Cargando…
Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol
INTRODUCTION: The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. When diagnosed, many patients already have organ damage or advance subclinical atherosclerosis. An early diagnosis could allow the implementation of lifestyle changes and treatment options aimed at delaying the p...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521512/ https://www.ncbi.nlm.nih.gov/pubmed/26220868 http://dx.doi.org/10.1136/bmjopen-2014-007195 |
_version_ | 1782383824473161728 |
---|---|
author | Salinero-Fort, Miguel Ángel de Burgos-Lunar, Carmen Mostaza Prieto, José Lahoz Rallo, Carlos Abánades-Herranz, Juan Carlos Gómez-Campelo, Paloma Laguna Cuesta, Fernando Estirado De Cabo, Eva García Iglesias, Francisca González Alegre, Teresa Fernández Puntero, Belén Montesano Sánchez, Luis Vicent López, David Cornejo Del Río, Víctor Fernández García, Pedro J Sabín Rodríguez, Concesa López López, Silvia Patrón Barandío, Pedro |
author_facet | Salinero-Fort, Miguel Ángel de Burgos-Lunar, Carmen Mostaza Prieto, José Lahoz Rallo, Carlos Abánades-Herranz, Juan Carlos Gómez-Campelo, Paloma Laguna Cuesta, Fernando Estirado De Cabo, Eva García Iglesias, Francisca González Alegre, Teresa Fernández Puntero, Belén Montesano Sánchez, Luis Vicent López, David Cornejo Del Río, Víctor Fernández García, Pedro J Sabín Rodríguez, Concesa López López, Silvia Patrón Barandío, Pedro |
author_sort | Salinero-Fort, Miguel Ángel |
collection | PubMed |
description | INTRODUCTION: The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. When diagnosed, many patients already have organ damage or advance subclinical atherosclerosis. An early diagnosis could allow the implementation of lifestyle changes and treatment options aimed at delaying the progression of the disease and to avoid cardiovascular complications. Different scores for identifying undiagnosed diabetes have been reported, however, their performance in populations of southern Europe has not been sufficiently evaluated. The main objectives of our study are: to evaluate the screening performance and cut-off points of the main scores that identify the risk of undiagnosed T2DM and prediabetes in a Spanish population, and to develop and validate our own predictive models of undiagnosed T2DM (screening model), and future T2DM (prediction risk model) after 5-year follow-up. As a secondary objective, we will evaluate the atherosclerotic burden of the population with undiagnosed T2DM. METHODS AND ANALYSIS: Population-based prospective cohort study with baseline screening, to evaluate the performance of the FINDRISC, DANISH, DESIR, ARIC and QDScore, against the gold standard tests: Fasting plasma glucose, oral glucose tolerance and/or HbA1c. The sample size will include 1352 participants between the ages of 45 and 74 years. Analysis: sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio positive, likelihood ratio negative and receiver operating characteristic curves and area under curve. Binary logistic regression for the first 700 individuals (derivation) and last 652 (validation) will be performed. All analyses will be calculated with their 95% CI; statistical significance will be p<0.05. ETHICS AND DISSEMINATION: The study protocol has been approved by the Research Ethics Committee of the Carlos III Hospital (Madrid). The score performance and predictive model will be presented in medical conferences, workshops, seminars and round table discussions. Furthermore, the predictive model will be published in a peer-reviewed medical journal to further increase the exposure of the scores. |
format | Online Article Text |
id | pubmed-4521512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45215122015-08-05 Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol Salinero-Fort, Miguel Ángel de Burgos-Lunar, Carmen Mostaza Prieto, José Lahoz Rallo, Carlos Abánades-Herranz, Juan Carlos Gómez-Campelo, Paloma Laguna Cuesta, Fernando Estirado De Cabo, Eva García Iglesias, Francisca González Alegre, Teresa Fernández Puntero, Belén Montesano Sánchez, Luis Vicent López, David Cornejo Del Río, Víctor Fernández García, Pedro J Sabín Rodríguez, Concesa López López, Silvia Patrón Barandío, Pedro BMJ Open Public Health INTRODUCTION: The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. When diagnosed, many patients already have organ damage or advance subclinical atherosclerosis. An early diagnosis could allow the implementation of lifestyle changes and treatment options aimed at delaying the progression of the disease and to avoid cardiovascular complications. Different scores for identifying undiagnosed diabetes have been reported, however, their performance in populations of southern Europe has not been sufficiently evaluated. The main objectives of our study are: to evaluate the screening performance and cut-off points of the main scores that identify the risk of undiagnosed T2DM and prediabetes in a Spanish population, and to develop and validate our own predictive models of undiagnosed T2DM (screening model), and future T2DM (prediction risk model) after 5-year follow-up. As a secondary objective, we will evaluate the atherosclerotic burden of the population with undiagnosed T2DM. METHODS AND ANALYSIS: Population-based prospective cohort study with baseline screening, to evaluate the performance of the FINDRISC, DANISH, DESIR, ARIC and QDScore, against the gold standard tests: Fasting plasma glucose, oral glucose tolerance and/or HbA1c. The sample size will include 1352 participants between the ages of 45 and 74 years. Analysis: sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio positive, likelihood ratio negative and receiver operating characteristic curves and area under curve. Binary logistic regression for the first 700 individuals (derivation) and last 652 (validation) will be performed. All analyses will be calculated with their 95% CI; statistical significance will be p<0.05. ETHICS AND DISSEMINATION: The study protocol has been approved by the Research Ethics Committee of the Carlos III Hospital (Madrid). The score performance and predictive model will be presented in medical conferences, workshops, seminars and round table discussions. Furthermore, the predictive model will be published in a peer-reviewed medical journal to further increase the exposure of the scores. BMJ Publishing Group 2015-07-28 /pmc/articles/PMC4521512/ /pubmed/26220868 http://dx.doi.org/10.1136/bmjopen-2014-007195 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Public Health Salinero-Fort, Miguel Ángel de Burgos-Lunar, Carmen Mostaza Prieto, José Lahoz Rallo, Carlos Abánades-Herranz, Juan Carlos Gómez-Campelo, Paloma Laguna Cuesta, Fernando Estirado De Cabo, Eva García Iglesias, Francisca González Alegre, Teresa Fernández Puntero, Belén Montesano Sánchez, Luis Vicent López, David Cornejo Del Río, Víctor Fernández García, Pedro J Sabín Rodríguez, Concesa López López, Silvia Patrón Barandío, Pedro Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol |
title | Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol |
title_full | Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol |
title_fullStr | Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol |
title_full_unstemmed | Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol |
title_short | Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol |
title_sort | validating prediction scales of type 2 diabetes mellitus in spain: the spredia-2 population-based prospective cohort study protocol |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521512/ https://www.ncbi.nlm.nih.gov/pubmed/26220868 http://dx.doi.org/10.1136/bmjopen-2014-007195 |
work_keys_str_mv | AT salinerofortmiguelangel validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT deburgoslunarcarmen validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT mostazaprietojose validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT lahozrallocarlos validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT abanadesherranzjuancarlos validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT gomezcampelopaloma validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT lagunacuestafernando validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT estiradodecaboeva validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT garciaiglesiasfrancisca validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT gonzalezalegreteresa validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT fernandezpunterobelen validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT montesanosanchezluis validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT vicentlopezdavid validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT cornejodelriovictor validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT fernandezgarciapedroj validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT sabinrodriguezconcesa validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT lopezlopezsilvia validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT patronbarandiopedro validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol AT validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol |